Leukapheresis Market Size & Growth Forecast 2026–2035, By Segments (Application, Product Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Leukapheresis Market size was valued at USD 227.95 Million in 2025 and is anticipated to grow at a 10.9% CAGR from 2026 to 2035, crossing USD 641.44 Million by 2035. The industry revenue for 2026 is estimated at USD 250.11 million.
Get more details on this report
Request Free Sample ReportLeukapheresis Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for a 39.07% share in 2025, supported by established apheresis infrastructure, specialized centers, and strong procedural adoption across healthcare settings.
- Asia Pacific is projected to grow at a 12.21% CAGR, driven by expanding healthcare capacity, advanced blood collection adoption, and increasing access to specialized centers.
Segment Momentum
- Research Application held a 74.54% market share in 2025 due to its established role in cell isolation, sample preparation, and laboratory workflows requiring consistent, high-quality white blood cell collection.
- Leukapheresis Disposables are the fastest-growing product type because every procedure requires new disposable components, creating continuous demand that rises alongside expanding research and clinical procedure volumes.
Market Expansion Drivers
- Rising prevalence of leukemia and autoimmune disorders increasing demand for leukapheresis procedures.
- Advancements in automated leukapheresis systems improving collection efficiency and patient safety outcomes.
- Growing adoption of CAR-T cell therapies expanding demand for high-quality cell collection technologies.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Prominent players in the leukapheresis market include Terumo BCT, Inc. (United States), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (United States), Miltenyi Biotec GmbH (Germany), Charles River Laboratories International, Inc. (United States), Lonza Group AG (Switzerland), Asahi Kasei Medical Co., Ltd. (Japan), Macopharma SA (France), Grifols, S.A. (Spain).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As diagnosis and treatment volumes rise for hematologic cancers and severe autoimmune conditions, the leukapheresis market benefits from a larger pool of patients requiring targeted white blood cell removal or collection as part of disease management and therapy preparation. In practice, hospitals and specialty centers increase procedure capacity when leukapheresis becomes necessary for reducing excessive leukocyte burden, managing treatment-related complications, or obtaining cellular material for downstream therapeutic use. This steady clinical pull reinforces market demand for devices, disposables, and procedure-support services tied directly to routine care pathways in oncology and immunology.
Advancements in automated leukapheresis systems improving collection efficiency and patient safety outcomes
Technology improvements in automation are reshaping purchasing decisions in the leukapheresis market by making procedures more consistent, less labor-intensive, and easier to integrate into high-throughput clinical settings. Automated leukapheresis systems help providers standardize collection parameters, reduce operator variability, and better manage patient-specific factors during treatment, which is especially important in fragile oncology populations. As centers prioritize workflow reliability and safer collection protocols, these systems support market expansion by encouraging equipment upgrades and broader use in both therapeutic and collection-oriented applications.
Growing adoption of CAR-T cell therapies expanding demand for high-quality cell collection technologies
The shift toward CAR-T treatment is creating a strong upstream requirement in the leukapheresis market because the quality of collected starting material directly affects manufacturing success, scheduling, and treatment readiness. Cell therapy programs depend on leukapheresis platforms that can reliably harvest viable, well-characterized cellular material from heavily treated patients, pushing providers to favor systems with tighter collection control and dependable performance. This is influencing market adoption toward advanced devices and specialized consumables that align with the operational demands of personalized cell therapy workflows.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of leukemia and autoimmune disorders increasing demand for leukapheresis procedures | 1.90% | High | North America, Asia Pacific | High | Near Term |
| Advancements in automated leukapheresis systems improving collection efficiency and patient safety outcomes | 1.70% | Moderate | Europe, North America | Medium | Mid Term |
| Growing adoption of CAR-T cell therapies expanding demand for high-quality cell collection technologies | 1.50% | High | North America, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 39.07% share of the leukapheresis market in 2025, supported by the region’s established apheresis infrastructure, broad presence of specialized blood collection and transfusion centers, and high procedural familiarity across hospital and clinical settings. Market activity is reinforced by the practical concentration of advanced healthcare facilities that can perform donor screening, cell collection, processing, and downstream therapeutic use within coordinated care pathways. This operating environment helps sustain procedure volumes and supports continued demand for leukapheresis systems and related consumables.
Asia Pacific is projected to expand at a 12.21% CAGR over the forecast period, with growth in the leukapheresis market being fueled by rising adoption of advanced blood component collection practices and the ongoing development of healthcare capacity across major regional economies. Expansion is being shaped by a gradual increase in access to specialized treatment centers and collection capabilities, which improves the region’s ability to perform leukocyte separation procedures in practice. As clinical infrastructure broadens and procedural adoption deepens, demand is accelerating for equipment and disposables used in leukapheresis workflows.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Treatment IntegrationGermany integrates leukapheresis into specialized clinical care supported by advanced transfusion medicine and research networks. The country prioritizes standardized procedures and high-quality collection systems that support expanding cellular therapy and therapeutic apheresis applications.
France 🇫🇷
Specialized Care ExpansionFrance advances leukapheresis use through specialized hospitals and collaborative research programs focused on oncology and immune disorders. The market favors technologies that enhance procedural consistency while supporting evolving therapeutic protocols.
Italy 🇮🇹
Hospital-Based AdoptionItaly continues expanding leukapheresis capabilities within major medical centers managing hematological diseases and transplant procedures. Healthcare providers seek dependable systems that improve operational efficiency and accommodate increasing demand for advanced therapeutic interventions.
Japan 🇯🇵
Regenerative Medicine SupportJapan aligns leukapheresis adoption with its strong regenerative medicine ecosystem and clinical research activities. Healthcare providers focus on reliable cell collection platforms that meet stringent quality expectations while supporting personalized treatment development.
South Korea 🇰🇷
Cell Therapy InfrastructureSouth Korea strengthens leukapheresis demand through expanding biotechnology investments and commercial cell therapy production. The country encourages healthcare facilities to adopt efficient collection systems that support both clinical applications and manufacturing requirements.
United States 🇺🇸
Clinical Innovation HubThe U.S. emphasizes wider adoption of leukapheresis across cell therapy manufacturing, hematology, and immunology applications. Hospitals, research institutions, and biopharmaceutical companies continue investing in advanced collection technologies that improve workflow efficiency and product consistency.
Segment Leadership and Growth Trends
Leukapheresis Market Share (%), Application, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportResearch Application held a 74.54% share of the leukapheresis market in 2025, making it the leading application segment. This leadership is maintained through the routine use of leukapheresis in cell isolation and sample preparation workflows across research settings, where consistent access to viable white blood cells is essential for immunology, oncology, and translational studies. The segment’s strong share reflects the established role of research-driven demand in the leukapheresis market, particularly where controlled collection processes and repeatable sample quality are critical to laboratory and clinical investigation activity.
Therapeutics Application is emerging as the fastest-growing segment in the leukapheresis market as clinical use cases gain traction beyond research-centered demand. Its momentum is underpinned by the increasing practical relevance of leukapheresis in treatment pathways that require targeted removal or collection of leukocytes under monitored medical settings. Compared with research applications, therapeutics application growth is being driven more directly by patient-care integration, which creates expanding demand as healthcare providers adopt leukapheresis procedures for specialized clinical management.
Product Type Segment Analysis: Leukapheresis Devices (Largest Segment) vs Leukapheresis Disposables (Fastest-Growing Segment)
In 2025, Leukapheresis Devices accounted for a 67.05% share of the leukapheresis market, positioning them as the largest product type segment. Their leading share is tied to the central role of devices in enabling the full leukapheresis procedure, since collection, separation, and operational control depend on installed equipment capacity. Leadership in the leukapheresis market is therefore maintained by the essential nature of these systems within blood centers, hospitals, and research facilities where procedural reliability and workflow continuity depend on device availability.
Leukapheresis Disposables represent the fastest-growing product type in the leukapheresis market, underpinned by their recurring consumption profile across every procedure. Growth is accelerating because each leukapheresis session requires fresh disposable components, making demand rise in step with procedure volumes rather than installed base alone. Relative to devices, disposables gain momentum from ongoing replacement needs and routine operational usage, which creates a more continuous demand pattern as leukapheresis activity expands across research and clinical environments.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Research Application, Therapeutics Application | Research Application | Therapeutics Application |
| Product Type | Leukapheresis Devices, Leukapheresis Disposables | Leukapheresis Devices | Leukapheresis Disposables |
| End-use | Blood Centers, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics | Hospitals & Clinics | Pharmaceutical & Biotechnology Companies |
Competitive Landscape and Market Positioning
1. Terumo BCT Inc. (United States)
2. Fresenius SE & Co. KGaA (Germany)
3. Haemonetics Corporation (United States)
4. Miltenyi Biotec GmbH (Germany)
5. Charles River Laboratories International Inc. (United States)
6. Lonza Group AG (Switzerland)
7. Asahi Kasei Medical Co. Ltd. (Japan)
8. Macopharma SA (France)
9. Grifols S.A. (Spain)
The leukapheresis market is witnessing strategic expansion driven by rising demand for cell-based therapies and advanced blood component separation technologies. Companies are enhancing automated collection systems and improving workflow efficiency to support growing applications in immunotherapy and regenerative medicine. Consolidation activities and investments in specialized treatment infrastructure are also contributing to stronger competitive positioning within the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Bristol Myers Squibb | Mar-24 | The FDA approved Breyanzi, a CAR-T cell therapy for specific leukemia and lymphoma indications. The therapy utilizes a leukapheresis-based collection process to harvest patient white blood cells, reinforcing the essential role of leukapheresis equipment and procedure standardization in the clinical manufacturing and supply chain of personalized cell-based immunotherapies. |
| Terumo Blood and Cell Technologies | Aug-23 | The FDA approved the Reveos Automated Whole Blood Processing System, which enables the efficient separation of whole blood into white blood cells and other components. This automated technology enhances blood processing capabilities and supply chain resilience for clinical cell collection, supporting the growing demand for high-quality source material in downstream cell and gene therapy manufacturing. |
| Akadeum Life Sciences | May-23 | Akadeum Life Sciences launched a specialized product line utilizing BACS Microbubble technology to streamline the isolation of T cells and PBMCs from leukapheresis material. By eliminating the need for traditional centrifugation and lysis steps, this innovation reduces processing time and enhances cell viability, addressing critical workflow inefficiencies in research-grade cell therapy development. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Leukapheresis Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Leukapheresis Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow large is the leukapheresis market?
What is the anticipated CAGR of the leukapheresis industry?
How are rising hematologic disorder treatment needs driving leukapheresis market expansion?
How are automated systems and cell therapy trends influencing leukapheresis technology adoption?
Why is Research Application the leading segment in the leukapheresis market?
Which product type is growing fastest in the leukapheresis market?
Why does North America hold the largest leukapheresis market share?
What is driving Asia Pacific growth in the leukapheresis market?
Who holds a significant market share in the leukapheresis landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization